603368 Guangxi LiuYao Group
- 22.79
- -0.01-0.04%
Guangxi LiuYao Group News
Liu Pharmaceutical Group (603368.SH): Plans to add about 100 new stores throughout the year
Gelonghui, April 30, 丨 Liuyao Group (603368.SH) said at an investor exchange meeting that the company's retail sector will further improve the store layout in 2024, plan to add about 100 new stores throughout the year, continue to optimize variety management, maintain the advantages of differentiated varieties, increase the sales share of core strategic varieties, self-produced Chinese herbal medicine tablets, etc. in stores, and optimize the variety structure. In addition, continue to develop specialized services such as chronic disease management, implement digital health services such as smart patient education and AI consultation as soon as possible, give full play to the advantages of self-built Internet hospitals, and carry out prescription outreach projects to form “Medical+Pharmaceutical+
Liu Pharmaceutical Group (603368.SH): At present, the company has cooperated with more than 30 core medical institutions in Guangxi on SPD projects
Gelonghui, April 30丨Liuyao Group (603368.SH) said at an investor exchange meeting that in the first quarter of 2024, the company will use the advantages of pharmaceutical device collaboration and batch zero collaboration to accelerate the introduction and promotion of innovative drugs, continue to deepen the market penetration, and actively carry out SPD projects for hospital equipment and consumables to increase the market share of equipment consumables. Currently, the company has cooperated with more than 30 core medical institutions in Guangxi on SPD projects. The aging population and the increase in residents' ability to pay for medical care lay the foundation for future growth in the pharmaceutical market. In the current situation where the medical device consumables market is still scattered, small, and numerous, the company's medical treatment in Guangxi
Guangxi Liuyao Gets Shanghai Bourse's Nod to Issue Shares
Shanghai Stock Exchange approved Guangxi Liuyao Group's (SHA:603368) plan to issue A shares to specific investors, according to the company's disclosure on the Shanghai bourse. The Chinese pharmaceuti
Estimating The Intrinsic Value Of Guangxi LiuYao Group Co., Ltd (SHSE:603368)
Key Insights Guangxi LiuYao Group's estimated fair value is CN¥21.40 based on 2 Stage Free Cash Flow to Equity Guangxi LiuYao Group's CN¥21.18 share price indicates it is trading at similar levels a
Liu Pharmaceutical Group (603368.SH): Net profit increased 20.7% year-on-year in 2023
Gelonghui, March 19丨Liuyao Group (603368.SH) announced its 2023 annual results report. During the reporting period, the company achieved total operating revenue of 208,011.9029 million yuan, an increase of 9.23% over the previous year; net profit attributable to shareholders of listed companies was 8467.639 million yuan, an increase of 20.70% over the previous year. In the pharmaceutical wholesale sector, the company strengthens supplier cooperation, seizes high-quality new products, actively expands SPD projects for pharmaceutical consumables, promotes the implementation of the collection and distribution model, and steadily increases the size of the wholesale market, especially the market share of equipment consumables. In the pharmaceutical retail sector, the company continues to expand to zero
Liu Pharmaceutical Group (603368.SH)'s net profit for 2023 was 847 million yuan, up 20.7% year on year
Liu Pharmaceutical Group (603368.SH) released its 2023 annual performance report. The company's total revenue was 208.12...
Investors Aren't Buying Guangxi LiuYao Group Co., Ltd's (SHSE:603368) Earnings
With a price-to-earnings (or "P/E") ratio of 8.6x Guangxi LiuYao Group Co., Ltd (SHSE:603368) may be sending very bullish signals at the moment, given that almost half of all companies in China have P
Retail Investors Who Hold 42% of Guangxi LiuYao Group Co., Ltd (SHSE:603368) Gained 6.7%, Insiders Profited as Well
Key Insights The considerable ownership by retail investors in Guangxi LiuYao Group indicates that they collectively have a greater say in management and business strategy 50% of the business is hel
These 4 Measures Indicate That Guangxi LiuYao Group (SHSE:603368) Is Using Debt Reasonably Well
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Liuyao Group (603368.SH): There is a business partnership with Daxanlin
Gelonghui, December 14|Liuyao Group (603368.SH) said on an interactive platform that the company has business cooperation with Daxanlin.
Liuyao Group (603368.SH)'s application for a fixed increase in shares was approved by the China Securities Regulatory Commission
Liuyao Group (603368.SH) issued an announcement. The company recently received an announcement from the China Securities Regulatory Commission...
Declining Stock and Decent Financials: Is The Market Wrong About Guangxi LiuYao Group Co., Ltd (SHSE:603368)?
With its stock down 5.2% over the past week, it is easy to disregard Guangxi LiuYao Group (SHSE:603368). But if you pay close attention, you might find that its key financial indicators look quite d
Liuyao Group (603368.SH): The implementation of the SPD project for hospital equipment consumables will be further accelerated this year
On October 31, Gelonghui Group (603368.SH) said at an investor exchange conference that the company's market share of medical device consumables in Guangxi is low, and there is plenty of room for growth. Therefore, in recent years, the company has increased its market expansion efforts in medical device consumables and test reagents, strengthened business resource collaboration between the drug side and the device side, and jointly promoted the development of hospital customers for device consumables and test reagents and the implementation of hospital SPD projects. The company will further accelerate the implementation of the SPD project for hospital equipment and consumables this year. It plans to have 18-22 tertiary hospitals and 20-30 second-tier hospitals in Guangxi
Liuyao Group (603368.SH): By the end of the third quarter of this year, the company had developed nearly 200 customers
Gelonghui, October 31, Liuyao Group (603368.SH) said at an investor exchange conference that the company's current hospital development work is progressing in an orderly manner. By the end of the third quarter of this year, the company had developed nearly 200 customers, including some medical institutions in Guangxi and some regional medical institutions outside the province. Next, the company will further accelerate the market layout of core hospitals in the region and promote sales volume.
Liuyao Group (603368.SH): At present, it has completed the registration and listing of more than 400 varieties
On October 31, Gelonghui Group (603368.SH) said at an investor exchange conference that in terms of production and sales of traditional Chinese medicine formula granules, the company has now completed the registration and listing of more than 400 varieties. In addition to national standard varieties and Guangxi provincial standard varieties, companies are simultaneously carrying out filing work in Guangdong, Sichuan, Chongqing and other regions. In terms of market development, the company's traditional Chinese medicine formula granules have relied on the company's hospital channel advantages to carry out extensive hospitalization work.
[BT Financial Report Instantaneous Analysis] Liuyao Group's 2023 Three-Quarter Report: Steady Growth in Performance, Significant Increase in Cash Flow
This financial report was announced on 2023-10-25 16:20:02 Guangxi Liuyao Group Co., Ltd. (stock code: 603368), which is mainly engaged in pharmaceutical distribution business, covering two major business segments: wholesale and retail. At the same time, the company is also actively developing upstream pharmaceutical industry business and is committed to the production and development of traditional Chinese medicine-related products such as traditional Chinese medicine, proprietary Chinese medicines, and traditional Chinese medicine formula granules. Driven by both industry development and policy support, the company's performance has maintained steady growth. In terms of assets and liabilities, at the end of the third quarter of 2023, Liuyao Group's total assets were 20.737 billion yuan, compared with 18 at the end of the previous year
Liu Pharmaceutical Group (603368.SH) released results and net profit of 675 million yuan for the first three quarters, up 17.26% year-on-year
Liu Pharmaceutical Group (603368.SH) disclosed its report for the third quarter of 2023. The company achieved operating income during the reporting period...
Guangxi LiuYao Group Co., Ltd's (SHSE:603368) Stock Price Dropped 5.6% Last Week; Individual Investors Would Not Be Happy
Key Insights Guangxi LiuYao Group's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 21 investors have a ma
Tianfeng Securities: The pharmaceutical distribution sector performed well in the first half of the year, and the retail and distribution sector achieved good growth
The core logic of the pharmaceutical distribution industry comes from valuation restoration under policy optimization. It is recommended to look at the changing trends of enterprises from a medium-term perspective.
The production capacity of the Liuyao Group (603368.SH) traditional Chinese medicine formula granule project reached 800-1000 tons
Liu Pharmaceutical Group (603368.SH) announced that the company has produced traditional Chinese medicine formula granules as of September 22, 2023...
Analysis
Price Target
No Data
